Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol: Trastuzumab deruxtecan | Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Trastuzumab deruxtecan for her2-positive gastric cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Trastuzumab deruxtecan for her2-positive gastric cancer

New Protocol: Trastuzumab deruxtecan for her2-positive gastric cancer
Study:
  • Open-label, randomized phase II trial (DESTINY-Gastric01)
  • Her2-positive gastric/GE junction adenoCa pts who received >=2 previous regimens including 5-FU, platinum, and trastuzumab
  • Trastuzumab deruxtecan (n= 125) vs. physician’s choice of irinotecan or PACLitaxel (n=62)
Efficacy:
  • Confirmed response: 43% [34% – 52%] vs. 12% [5% – 24%]
  • Median duration of confirmed response: 11.3 mos [5.6 mos – NE] vs. 3.9 mos [3.0 – 4.9 mos]
  • OS: 12.5 mos vs. 8.4 mos (HR: 0.59 [0.39 – 0.88])
Safety:
  • Grade 3-4 AEs: Neutropenia (51% vs. 24%), anemia (38% vs. 23%), thrombocytopenia (12% vs. 4%)

N Engl J Med 2020;382:2419.

Shitara K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

https://doi.org/10.1056/NEJMoa2004413

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More